RCS - Oxford Biomedica PLC - OXB present at Jefferies Healthcare Conference <Origin Href="QuoteRef">OXB.L</Origin>

Oxford BioMedicaAnnouncement

18/11/2015 09:41

RNS Number : 1227G
Oxford Biomedica PLC
18 November 2015
Oxford BioMedica to present at the Jefferies 2015 Global Healthcare Conference, London
Oxford, UK - 18 November 2015: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, announces that John Dawson, Chief Executive Officer, will be presenting at the Jefferies 2015 Global Healthcare Conference in London on 19 November 2015 at 2pm.The presentation will be made available on the Oxford BioMedica website after the presentation.
- Ends -
For further information, please contact:
Oxford BioMedica plc:
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Tel: +44 (0)1865 783 000
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton
Tel: +44 (0)20 3709 5700
Notes for editors
About Oxford BioMedica
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NRAGCBDBGSBBGUI